ARVO LIVE: CEO of RetinAI gives update on technological advances in ophthalmology

Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Carlos Ciller, PhD:

So, hi everyone. My name is Carlos Ciller. I'm the co-founder and CEO of RetinAI. We are a software company that is redefining the standard of healthcare using [the] latest technology in data management, artificial intelligence, and process automation. Today, some of the things that we are developing are accelerating drug development pipelines, for instance, making sure that you are bringing faster innovation from Phase 1, first in human clinical studies, all the way to the moment where they reach commercialization.

Some of these technology can also be used in order to support the development of clinical research. So clinical researchers are using our products and technology to elevate the quality of the physicians, the quality of the research. and interestingly, we also have solutions that enable you to support physicians during routine medical care. So for instance, especially in Europe, where our solutions were approved last year, or even in the United States, where our solutions were approved, also last year, we can provide a data management solution to digest all the data that is being collected in the clinic, apply additional AI analysis that is certified in some cases, for the European case, but is in the process of being certified in the United States. And last but not least, we can present all this information through a through a web browser. So it's available whenever you have something like a computer, your iPad, or wherever you are accessing your data from.

So we are very excited being here. A couple of days ago, we just announced a collaboration with Boehringer Ingelheim. They are using our technology in order to support AI developments in geographic atrophy. We have unique technology in geographic atrophy to support identifying the progression of different patients before it even happens. So you can use AI technology to identify the speed at which this is going to affect the fovea or which are going to be slow progresses. And, this is very interesting for the new upcoming GA tracks that are coming into the market now.